The
medical industry is growing rapidly with the rising concern of diseases and
makes this a richest market in the healthcare industry. However, with the more
development in the technology of medicine making the medical industry is
showing effective growth. According to the report analysis, ‘Duchenne
Muscular Dystrophy – Pipeline Review, H2 2018’ states that Duchenne muscular dystrophy is a
serious type of muscular dystrophy which causes muscles to gradually weaken
over time. Learning difficulties, fatigue, muscle weakness, intellectual
disability, progressive difficulty walking and several others are the major
signs and symptoms of this disease. Moreover, the caused muscles may look
larger because of increased fat content. Moreover, this disease affects nearly
about 5,000 males at the time of birth and the average life expectancy is 26
and with the proper care many can live into their 30s or 40s. In addition, Gene
Therapy is just like a treatment which is done early stages of study in humans.
Duchenne
muscular dystrophy is caused by the change or problem in one of your gene as
the genes carry important information of body which is important to make
proteins and carry out many different functions of body. It appears that
regions around the globe that do not have a strong risk factors which includes
gender and family history. In this respect Asia Pacific region has gather the
significant attention. The global instances described in the numerous health
care organizations in the recent years. Moreover, major portion of the Asian
countries reported cases of this disease along with European countries and the
Americas. Furthermore, significant number of cases is registered by the North
America region. Many other regions such as Africa have begun revolutionizing
health care centers form procuring this disease in the country and the
authorities of above countries have also started scattering warning and
awareness to the general public related to the harmful effects and causes of
this disease.
According
to the report it is observed that the major topics which are covered for this
disease includes Duchenne Muscular Dystrophy Therapeutic Products under
Development, Key Players in Duchenne Muscular Dystrophy Therapeutics, Duchenne
Muscular Dystrophy Pipeline Overview, Duchenne Muscular Dystrophy Pipeline,
Duchenne Muscular Dystrophy Pipeline Assessment. On the other hand, report also
covers major companies which are operating in this market produce the medicines
such as Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Avidity
Biosciences LLC, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, Biophytis
SA, Capricor Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR
Therapeutics, Cumberland Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Editas
Medicine Inc, Eloxx Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Fate
Therapeutics Inc, FibroGen Inc, Fulcrum Therapeutics Inc, Galapagos NV,
Genethon SA, GTx Inc, GW Pharmaceuticals Plc, Italfarmaco SpA, Milo
Biotechnology LLC, Mitobridge Inc, Mitochon Pharmaceuticals Inc, N-Gene
Research Laboratories Inc, NicOx SA, Nobelpharma Co Ltd, Novartis AG, NS Pharma
Inc, PeptiDream Inc, Pfizer Inc, Progenitor Therapeutics Ltd, PTC Therapeutics
Inc, ReveraGen BioPharma Inc, Santhera Pharmaceuticals Holding AG, Sarepta
Therapeutics Inc, Solid Biosciences Inc, SOM Biotech SL, Strykagen Corp, Summit
Therapeutics Plc, Taiho Pharmaceutical Co Ltd, Teijin Pharma Ltd, WAVE Life
Sciences Ltd and others.
In
a research it is observed that many of the key players is functioning well for
enabling the better treatment of this disease with the effective decision
marking and built clinical trials, conferences which is helpful for the victims
of this disease and for creating effective counter policies to gain competitive
benefits. Therefore, in the coming years it is expected that global market of
Duchenne muscular dystrophy healthcare pipeline will grow more significantly
over the forecasted period with the introduction of more related projects on
this disease.
For more information, click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91-9015378249